As those watching the resource space are no doubt aware, the first six months of 2014 saw quite a few junior miners make forays into the medical marijuana sector.

Encouragingly for those companies, swathes of investors have been only too eager to follow. However, many analysts believe that’s a problem, in part because the sector is so new, but also because there’s still so much bureaucratic red tape and uncertainty surrounding marijuana use, even for medical purposes.


It’s thus unsurprising that “caution” and “profit” were the words of the hour at Monday’s Canadian Investor Conference marijuana panel, which featured activist Jodie Emery, Daniel Kiselbach of Deloitte Tax Law, Midas Letter’s James West and Paul Pelosi, Jr. of Verde Science (OTCMKTS:VRCI).

Why be cautious?

Giving his take on the need for caution, West explained that, at least in Canada, there’s a disconnect between what licensed commercial growers think they can achieve and what is actually achievable. Specifically, he said, those growers “predict that they will realize a price of $8 per gram” when “probably 25,000” of the 38,000 medical marijuana users registered with Health Canada “have been on disability and paying less than $1 a gram from compassionate growers and suppliers.”

While that could be a “great opportunit[y]” for traders able to ride stocks up as they’re buoyed by marijuana-related plans, it also means that ultimately there will be a “very slow and consistent degradation for the sector as a whole” as companies that don’t follow through on those plans disappear.

On a similar note, Emery pointed out that companies hoping to grow marijuana “are being promised a marketplace that … does exist,” but is already being served. In her opinion, it will thus be tough for companies to make the money they’ve been promised unless the market expands via “legalization for all” or unless they can “offer something that people can’t get elsewhere.”

Kiselbach was a little more positive, pointing to Tweed Marijuana’s (TSXV:TWD) success after listing on the TSX Venture Exchange and commenting, “there are opportunities, at least at this point in time, for making money.” However, he said, companies must do “careful planning in order to be profitable,” and unfortunately many are not making an effort to do so.

Profitable opportunities

Those comments may sound daunting, but none of the panelists denied that profiting from medical marijuana is indeed possible. Here’s what they said when asked which companies they think are “doing it right.”

  • West: “The best-looking business plan I’ve seen yet belongs to a company called THC Bank, which focuses on protecting and preserving the genetic integrity of various strains of marijuana for growers.”
  • Kiselbach: Kiselbach again identified Tweed as a company that is making money.
  • Emery: Though she noted that she wasn’t there to offer stock picks, Emery did point to her own success at working “in the marijuana industry without actually dealing with marijuana itself.” She also emphasized the importance of supporting companies that advocate for full legalization.
  • Pelosi: “Investors do flock to corporations which have strong corporate governance,” said Pelosi. Additionally, he noted that corporate mission is important, as is growth potential for revenue, a quality he believes Verde Science certainly has.

Certainly some food for thought for investors watching the sector.

Stay tuned for a video interview with Jodie Emery. 

 

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article. 

Related reading: 

Investing in Marijuana: A High-risk Green Rush

Making the Switch: 3 Junior Mining CEOs Explain the Pull of Medical Marijuana

Deloitte Tax Law: What to Look for in a Medical Marijuana Company

Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States today announced the appointment of Marcum LLP (“Marcum”) as its independent registered public accounting firm, effective July 5, 2021 . Marcum was appointed following the resignation of MNP LLP (“MNP”) as the Company’s independent registered public accounting firm effective July 5, 2021 .

“We would like to thank MNP for their guidance and expertise over the past two years and we look forward to working with Marcum as the Company’s new independent registered public accounting firm,” stated Chief Financial Officer, Alex D’Amico.

Keep reading... Show less

Cannabis-infused beverages are not a new product concept, but this summer Canadian drink makers hope consumers will discover them for the first time.

Recreational cannabis beverages have beguiled Canadian producers through different avenues, and many continue to make investments. The promise of these drinks lies in the potential of a more welcoming option for new consumers who may be out of their depth with rolled-up dried flower.

Keep reading... Show less

In the news release, BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years, issued 07-Jul-2021 by BioHarvest Sciences Inc. over PR Newswire, we are advised by the company that an incorrect version of the release was issued inadvertently. The complete, corrected release follows:

BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years

Keep reading... Show less

Trulieve is the first medical cannabis operator to start planting in the state

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today that it commenced operations in West Virginia . The Company has begun cultivation at their 100,000 square foot size facility in Huntington, West Virginia .

Keep reading... Show less

– The Company demonstrates the efficiency and reliability of its BioFarming technology by reducing production cycle time for Cannabis from 14-23 weeks to 3-4 weeks.

– The Company’s BioFarming technology will allow the Company to harvest 13-17 cycles per year versus 2-4 cycles per year for conventional Cannabis agriculture.

Keep reading... Show less